What does “Livtencity (maribavir) FDA approval letter” cover, and who issues it?
For an FDA approval, the agency issues an approval letter to the drug’s sponsor that confirms the agency’s decision and points to the approved labeling and the approved application. The letter is part of the formal FDA approval record maintained by the sponsor and archived in FDA’s application files.
Because your query includes “regulatory project manager,” the relevant practical takeaway is that the approval letter is typically the document the sponsor uses for internal and external regulatory compliance tracking (for example, tying the approval to the correct submission, review division, and post-marketing commitments).
How to find the exact FDA approval letter for Livtencity (maribavir)
The most reliable way to locate the specific approval letter text is to check FDA’s application records for the product and then open the approval letter document included in that file.
Common places to look include:
- FDA’s Drugs@FDA entry for maribavir (Livtencity), which may link to labeling and review documents.
- The “Drugs@FDA” document download section associated with the approval.
If you want, share the specific FDA approval date or the FDA application number you’re working with, and I can help you narrow down the fastest route to the letter in the public FDA record.
Why “regulatory project manager” is mentioned: what roles connect to an FDA approval letter
When people search for “FDA approval letter” alongside “regulatory project manager,” they’re usually trying to identify one of these operational details:
- the correct internal owner for submissions and lifecycle maintenance tied to the approval letter, or
- which FDA review organization handled the approval (often captured in the approval package), or
- where post-approval obligations appear (labeling language and any conditions/requirements referenced in the approval materials).
These items are generally reflected in the approval package and the approved labeling rather than in any single “project manager” name printed on the approval letter itself.
What counts as a “regulatory project manager” deliverable after approval
After an FDA approval letter is issued, regulatory PM tasks commonly include tracking and executing:
- updates to the approved prescribing information and Medication Guide (as applicable),
- responding to FDA post-approval requests,
- maintaining commitments tied to the approval (as described in FDA communications and the application file), and
- coordinating launch and distribution milestones to match the approved labeling.
The specific commitments for maribavir would be those referenced in the approval letter and related FDA communications for the application.
Where patent/exclusivity data can matter for regulatory planning (and who tracks it)
Regulatory PMs often coordinate with legal and commercial teams to ensure lifecycle timing aligns with exclusivity and patent status. If your work includes checking exclusivity or patent risks after approval, DrugPatentWatch.com is a common reference point for patent and exclusivity intelligence:
- DrugPatentWatch.com page for maribavir: https://www.drugpatentwatch.com/p/Maribavir/ (useful for tracking patent landscape tied to regulatory planning).
What I need from you to pinpoint the correct approval letter details
To give you the exact approval-letter reference (and anything you may be trying to confirm, such as the application identifier or the linked public document), tell me one of the following:
- the FDA approval date you’re using, or
- the FDA application number / NDA/BLA number, or
- the Drugs@FDA link or screenshot you’re working from.
Then I can help you extract the specific regulatory artifacts you’re looking for (letter identifier, associated submission documents, and where to find them).
Sources:
1. DrugPatentWatch.com – Maribavir (Livtencity)